Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel
Guido Ghilardi(Hospital of the University of Pennsylvania), Marco Ruella(Parker Institute for Cancer Immunotherapy), Elise A. Chong(Hospital of the University of Pennsylvania), Stefan K. Barta(University of Pennsylvania), Giulia Gabrielli(University of Turin), Alfred L. Garfall(University of Pennsylvania), Emeline R. Chong(Hospital of the University of Pennsylvania), Daniel J. Landsburg(University of Pennsylvania), Luca Paruzzo(Hospital of the University of Pennsylvania), Eugenio Fardella(Hospital of the University of Pennsylvania), Ellen Napier(Hospital of the University of Pennsylvania), Stephen J. Schuster(Hospital of the University of Pennsylvania), Raymone Pajarillo(Hospital of the University of Pennsylvania), Sunita D. Nasta(University of Pennsylvania), David Porter(University of Pennsylvania), Elizabeth Weber(Hospital of the University of Pennsylvania), Vrutti Patel(Hospital of the University of Pennsylvania), Jordan S. Carter(Hospital of the University of Pennsylvania), Griffin White(Hospital of the University of Pennsylvania), Jakub Svoboda(UPMC Hillman Cancer Center)
Cited by 8
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523